Compare UVE & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | ORIC |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 1.1B |
| IPO Year | 1992 | 2020 |
| Metric | UVE | ORIC |
|---|---|---|
| Price | $31.25 | $10.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.78 |
| AVG Volume (30 Days) | 157.3K | ★ 1.2M |
| Earning Date | 10-23-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 70.32 | N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $1,580,798,000.00 | N/A |
| Revenue This Year | $1.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.36 | ★ N/A |
| Revenue Growth | ★ 4.61 | N/A |
| 52 Week Low | $18.72 | $3.90 |
| 52 Week High | $35.84 | $14.93 |
| Indicator | UVE | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 37.26 |
| Support Level | $31.80 | $10.45 |
| Resistance Level | $33.58 | $12.14 |
| Average True Range (ATR) | 1.02 | 0.81 |
| MACD | -0.45 | -0.09 |
| Stochastic Oscillator | 8.71 | 11.92 |
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.